August 1, 2013 / 8:26 PM / 4 years ago

Pacira Pharma pain drug fails late-stage trial

1 Min Read

(Reuters) - Pacira Pharmaceuticals Inc said its lead drug did not meet the main goal in a late-stage trial of reducing pain for patients undergoing a surgical procedure called posterolateral thoracotomy.

Pacira said the company did not meet the main goal of reducing pain scores over 72 hours, compared with a placebo.

The results are from a second late-stage study of the drug, Exparel, which is already approved as a single-dose injection to treat postsurgical pain.

Reporting By Vrinda Manocha in Bangalore; Editing by Maju Samuel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below